7.3.2. local therapy metastases metastatic rcc. sr local treatment metastases rcc organ undertaken . interventions included metastasectomy, various radiotherapy modalities, local treatment. outcomes assessed os, css pfs, local symptom control aes. risk-of-bias assessment conducted . 2,235 studies identified sixteen non-randomised comparative studies included. data heterogeneous meta-analyse. considerable variation type distribution systemic therapies (cytokines vegf-inhibitors) reporting results. subsequent sr change quality evidence . 7.3.2.1. complete versus no/incomplete metastasectomy sr, including eight studies, compared complete vs. and/or incomplete metastasectomy rcc metastases various organs [510-517]. one study complete resection achieved 45% metastasectomy cohort, compared metastasectomy . non-surgical modalities applied. six studies [511-513,515-517] reported significantly longer median os css following complete metastasectomy (the median value os css 40.75 months, range 23-122 months) compared incomplete and/or metastasectomy (the median value os css 14.8 months, range 8.4-55.5 months). two remaining studies, one showed significant difference css complete metastasectomy, one reported longer median os metastasectomy albeit p-value provided. 7.3.2.2. local therapies rcc bone metastases three studies identified, one compared single-dose image-guided radiotherapy (igrt) hypofractionated igrt patients rcc bone metastases . single-dose igrt (> 24 gy) significantly better 3-year actuarial local pfs rate, also shown cox regression analysis. another study compared metastasectomy/curettage local stabilisation surgery solitary rcc bone metastases various locations . significantly higher five-year css rate observed intervention group. adjusting prior nephrectomy, gender age, multivariable analysis still favoured metastasectomy/ curettage stabilisation. third study compared efficacy durability pain relief single- dose stereotactic body radiotherapy (sbrt) conventional radiotherapy patients rcc bone metastases spine . pain, orr, time-to-pain relief duration pain relief similar. 7.3.2.3. local therapies rcc brain metastases two studies rcc brain metastases included. three-arm study compared stereotactic radiosurgery (srs) vs. whole brain radiotherapy (wbrt) vs. srs wbrt . group subdivided recursive partitioning analysis (rpa) classes iii (i favourable, ii moderate iii poor patient status). two- year os intra-cerebral control equivalent patients treated srs alone srs plus wbrt. treatments superior wbrt alone general study population rpa subgroup analyses. comparison srs vs. srs wbrt subgroup analysis rpa class showed significantly better 2-year os intra-cerebral control srs plus wbrt based three participants. study compared fractionated stereotactic radiotherapy (fsrt) metastasectomy conventional radiotherapy conventional radiotherapy alone . several patients groups underwent alternative surgical non-surgical treatments initial treatment. one-, two- three-year survival rates higher significantly fsrt metastasectomy conventional radiotherapy, conventional radiotherapy alone. fractionated stereotactic radiotherapy result significantly better two-year local control rate compared metastasectomy plus conventional radiotherapy. stereotactic radiotherapy (srt) median physical dose 20 (18-30) gy biologically effective dose (ded10) 63.3 (45-125) gy median (range) 1 (1-6) fractions 1-5 brain metastases safe also ici targeted therapy . targeted therapy paused one-third patients 2-21 days. local control sites, including extracranial, 75% one year. one year, 62% patients remained systemic therapy time srt, frequent ici therapy compared targeted therapy (83% vs. 36%; p = 0.035). grade iv v toxicity observed. 7.3.2.4. embolisation metastases embolisation prior resection hypervascular bone spinal metastases reduce intra-operative blood loss . selected patients painful bone paravertebral metastases, embolisation relieve symptoms (see recommendation section 7.1.2.2.4). 7.3.2.5. stereotactic radiotherapy oligo-recurrent oligo-progressive metastases sterotatic radiotherapy used oligoprogression (i.e. limited number metastasis progression, sites controlled systemic therapy) oligonmetastatic recurrences. two srs single arm studies conducted . non comparative nature studies included sr allow definate conclusions. retrospective analysis 207 patients oligo-recurrent oligo-progressive lesions mainly bones lungs without systemic therapy (mainly targeted therapy) demonstrated two-year local control rate 78.3% (95% ci: 72.5-83.0). one, two three-year local control rates 89.4%, 80.1% 76.6% oligo-recurrent patients, 82.7%, 76.9% 64.3% oligo-progressive disease, respectively. median applied biologically effective dose (bed) 10 60 gy. median time subsequent systemic therapy 13.9 months median pfs 37.9 months. grade iii higher toxicities reported . similar results oligo-progressive mrcc reported single-arm prospective study including 37 patients imdc favourable- intermediate risk one-year local control irradiated lesions 93% (95% ci: 71-98%) median time change systemic tki therapy 12.6 months (95% ci: 9.6-17.4 months). median therapy prior study entry 18.6 months therapy discontinued srt. median bed10 72 gy, corresponding srt dose 40 gy 5 fractions. median pfs 9.3 months reported grade iii acute late toxicities . several rcts sbrt oligometastatic setting ongoing. 7.3.2.6. adjuvant treatment cm0 patients metastasectomy patients metastasectomy evidence disease (cm0) high risk relapse. recent attempts reduce rfs randomised prospective phase ii trials sorafonib pazopanib metastasectomy demonstrate improvement rfs . keynote-564 included small percentage patients treated nephrectomy complete metastasectomy within one year primary diagnosis (6% experimental arm 6% placebo arm) . metachronous interval < 1 year recurrences following surgery curative intent poor prognostic factor imdc classification [. systemic therapy based immune combinations stronger levels evidence surgery intermediate/advanced disease setting . also, tki- driven adjuvant trials metastasectomy shown dfs os benefit . results single-agent pembrolizumab post-surgery metastatic disease therefore difficult interpret due small subgroup. nevertheless, dfs hr 0.29 (95% ci: 0.12-0.69) favour resection m1 ned plus pembrolizumab shows patients subclinical, progressive, disease subjected metastasectomy benefit adjuvant systemic therapy pembrolizumab. based current data cannot concluded patients oligo-progressive disease, metastasectomy within first year initial diagnosis primary subsequent adjuvant pembrolizumab superior period observation dual io-based combination first-line therapy upon progression. data tki era suggest patients oligometastatic disease recurrence observed median sixteen months systemic therapy required practice common real-world settings (30%) . addition, possible metastasectomy may lead poorer outcomes compared systemic therapy approaches relapse within first twelve months presentation synchronous (oligo- metastatic disease attributed imdc intermediate risk-group. panel therefore encourage metastasectomy adjuvant pembrolizumab population recurrent disease within one year primary surgery. careful reassessment disease status rule rapid progressive disease performed. data another adjuvant ici study pd-l1 inhibitor atezolizumab (immotion010) also included m1 ned subgroup showed dfs advantage . result underscores need caution treatment m1 ned subgroup. 7.3.2.7. summary evidence recommendations local therapy metastases metastatic rcc summary evidenceleretrospective comparative studies point towards benefit complete metastasectomy mrcc patients terms os, css delay systemic therapy.3a single-arm prospective retrospective study support oligometastases observed 16 months systemic therapy required due progression.2aradiotherapy bone brain metastases rcc induce significant relief local symptoms (e.g. pain).3tyrosine kinase inhibitors treatment metastasectomy patients evidence disease improve rfs compared placebo observation.1b recommendationsstrength ratingto control local symptoms, offer ablative therapy, including metastasectomy, patients metastatic disease favourable disease factors complete resection achievable.weakoffer stereotactic radiotherapy clinically relevant bone- brain metastases local control symptom relief.weakdo offer tyrosine kinase inhibitor treatment mrcc patients metastasectomy evidence disease.strongperform confirmatory axial scan disease status prior metastasectomy rule rapid progressive metastatic disease requires systemic treatment.weakbefore initiating systemic therapy oligometastases cannot resected, discuss patient period observation progression confirmed.weak